Tracks Korean bio-pharma companies with the highest technology licensing deal values over the past five years.
Alteogen Inc. approved a 30% bonus issue, allocating 0.3 new shares per existing share to shareholders of record on 2026-08-06. The company’s shares were temporarily halted on 2026-07-16 following the announcement, and the new shares are scheduled to list on 2026-08-20.
Analysts forecast Q2 2026 results will meet market consensus on 2026-08-19 with an estimated ≥1% price impact as results align with expectations forecasted.
Q2 2026 earnings release reflecting the upfront payment from the Agios licensing deal, which is estimated to have a medium impact on cash flow, scheduled.
Q2 2026 earnings release is scheduled.
Kolon TissueJin is scheduled to announce top-line results from the U.S. Phase 3 clinical trial of TG-C (Invossa) on July 31, 2026; this pivotal outcome is estimated to have a >10% price impact, expected
2Q 2026 earnings release on 2026-07-29; analysts forecast a significant profit increase due to the recognition of a large, one-time technology export contract fee. High importance is estimated due to the expected >10% price impact from the revenue surge, forecasted and scheduled.
Partner Johnson & Johnson announced that Q2 2026 global sales of the Leclaza (lazertinib) combination therapy increased by 60.8% year-over-year to $289 million, signaling a rise in royalty income for Yuhan; estimated >5% price impact due to significant revenue growth, expected.
Announced the temporary postponement of the company's planned relocation from the KOSDAQ to the KOSPI market on July 16, 2026, citing shareholder value.
The patent term extension for the key substance and crystalline form patents of the gastroesophageal reflux disease drug 'Pexuclu' was denied on 2026-07-15, potentially accelerating the entry of generic competitors; estimated price impact of 5-10% due to future revenue risk, expected.
Announced a joint research project with SK Telecom that successfully used AI to discover initial active substances for anti-cancer drugs, shortening the typical research period from 1-2 years to about 5 months.
Multiple securities analysts forecast that Chong Kun Dang's Q2 2026 earnings will show revenue growth driven by Wegovy but declining profitability due to costs; low impact expected as margin pressure is partially priced in, forecasted.
On June 26, 2026, the Fair Trade Commission closed its investigation into Daewoong's new 'block-type' distribution policy without taking action, resolving a dispute with the Korea Pharmaceutical Distribution Association; estimated price impact of 1-5% due to reduced legal uncertainty, expected.